Back to Search
Start Over
Adjuvant 131I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial
- Source :
- The Lancet Gastroenterology & Hepatology; June 2020, Vol. 5 Issue: 6 p548-560, 13p
- Publication Year :
- 2020
-
Abstract
- Effective adjuvant treatment after hepatectomy for hepatocellular carcinoma (HCC) is an important area of research. Radioactive iodine (131I)-labelled metuximab is a radiolabelled monoclonal antibody against the CD147 (also known as basigin or HAb18G) antigen that is expressed in HCC. We aimed to examine the role of 131I-metuximab as an adjuvant therapy after HCC resection.
Details
- Language :
- English
- ISSN :
- 24681253
- Volume :
- 5
- Issue :
- 6
- Database :
- Supplemental Index
- Journal :
- The Lancet Gastroenterology & Hepatology
- Publication Type :
- Periodical
- Accession number :
- ejs53235937
- Full Text :
- https://doi.org/10.1016/S2468-1253(19)30422-4